{"content":"<li class=\"n-box-item date-title\" data-end=\"1538107199\" data-start=\"1538020800\" data-txt=\"Monday, December 23, 2019\">Thursday, September 27, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3393608\" data-ts=\"1538098935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBIO\" target=\"_blank\">XBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393608-xenetic-biosciences-files-for-mixed-shelf-offering-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xenetic Biosciences files for mixed shelf offering; shares down 5% after hours</a></h4><ul><li>Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) slips&nbsp;<font color='red'>5%</font>&nbsp;after hours following the filing of a&nbsp;<a href=\"https://www.sec.gov/Archives/edgar/data/1534525/000168316818002876/xenetic_s3.htm\" target=\"_blank\">prospectus </a>for $50M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393608\" data-linked=\"Xenetic Biosciences files for mixed shelf offering; shares down 5% after hours\" data-tweet=\"$XBIO - Xenetic Biosciences files for mixed shelf offering; shares down 5% after hours https://seekingalpha.com/news/3393608-xenetic-biosciences-files-for-mixed-shelf-offering-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3393608-xenetic-biosciences-files-for-mixed-shelf-offering-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393599\" data-ts=\"1538084428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPRO\" target=\"_blank\">SPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393599-after-hours-gainers-losers-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (09/27/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/SPRO' title='Spero Therapeutics, Inc.'>SPRO</a> <font color='green'>+10.9%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+7.6%</font>. <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color='green'>+6.7%</font>. <a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a> <font color='green'>+4.6%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+3.3%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/IGT' title='International Game Technology'>IGT</a> <font color='red'>-3.8%</font>. <a href='https://seekingalpha.com/symbol/LXP' title='Lexington Realty Trust'>LXP</a> <font color='red'>-3.6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393599\" data-linked=\"After Hours Gainers / Losers (09/27/2018)\" data-tweet=\"$SPRO $SPRO $IGC - After Hours Gainers / Losers (09/27/2018) https://seekingalpha.com/news/3393599-after-hours-gainers-losers-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393599-after-hours-gainers-losers-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393589\" data-ts=\"1538081002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIFE\" target=\"_blank\">LIFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393589-atyr-pharma-sets-indication-for-atyr1923-study-shares-up-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ATyr Pharma sets indication for ATYR1923 study; shares up 4% after hours</a></h4><ul><li>ATyr Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma'>LIFE</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;after hours following its <a href=\"https://seekingalpha.com/pr/17284095-atyr-pharma-announces-pulmonary-sarcoidosis-disease-indication-phase-1b-2a-clinical-study\" target=\"_blank\">announcement </a>that it has chosen pulmonary sarcoidosis as the disease indication for its upcoming Phase 1/2 clinical trial evaluating lead candidate <a href=\"https://www.atyrpharma.com/programs/atyr1923/\" target=\"_blank\">ATYR1923</a>. The study should launch next quarter.</li><li><a href=\"https://www.hopkinsmedicine.org/healthlibrary/conditions/respiratory_disorders/pulmonary_sarcoidosis_85,P01325\" target=\"_blank\">Pulmonary sarcoidosis</a> in a rare inflammatory condition affecting the lungs that can lead to pulmonary fibrosis (scarring).</li></ul><div class=\"tiny-share-widget\" data-id=\"3393589\" data-linked=\"ATyr Pharma sets indication for ATYR1923 study; shares up 4% after hours\" data-tweet=\"$LIFE - ATyr Pharma sets indication for ATYR1923 study; shares up 4% after hours https://seekingalpha.com/news/3393589-atyr-pharma-sets-indication-for-atyr1923-study-shares-up-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3393589-atyr-pharma-sets-indication-for-atyr1923-study-shares-up-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393583\" data-ts=\"1538080396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGM\" target=\"_blank\">HTGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393583-htg-molecular-advancing-companion-diagnostic-qiagen-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HTG Molecular advancing companion diagnostic with Qiagen; shares up 2% after hours</a></h4><ul><li>HTG Molecular Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17284108-htg-molecular-announces-extension-precision-diagnostic-partnership-pdp-program-three\" target=\"_blank\">announcement </a>that its collaboration with QIAGEN (NASDAQ:<a href='https://seekingalpha.com/symbol/QGEN' title='Qiagen N.V.'>QGEN</a>) to develop a companion diagnostic test for an unnamed pharma company is moving ahead via an amendment to the third statement of work.</li><li>The amendment provides for the development of an investigational use-only assay, retrospective testing of trial samples, design verification and, if all goes according to plan, regulatory filings.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3273645-htg-molecular-qiagen-preparing-begin-development-work-next-gen-companion-diagnostic-test\" target=\"_blank\">HTG Molecular and Qiagen preparing to begin development work on next-gen companion diagnostic test for pharma firm; HTG up 21% premarket</a> (June 15, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393583\" data-linked=\"HTG Molecular advancing companion diagnostic with Qiagen; shares up 2% after hours\" data-tweet=\"$HTGM $HTGM $QGEN - HTG Molecular advancing companion diagnostic with Qiagen; shares up 2% after hours https://seekingalpha.com/news/3393583-htg-molecular-advancing-companion-diagnostic-qiagen-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3393583-htg-molecular-advancing-companion-diagnostic-qiagen-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393581\" data-ts=\"1538080236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGS\" target=\"_blank\">PRGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393581-progress-softwareminus-13-on-mixed-q3-downside-q4-and-fy-guides\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progress Software -13% on mixed Q3, downside Q4 and FY guides</a></h4><ul><li>        Progress Software (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a>)&nbsp;<font color='red'>drops 13%</font>&nbsp;aftermarket on Q3 results that beat EPS estimates but missed on revenue with a 2% Y/Y drop in sales. Downside Q4 guidance has revenue of $107M to $110M (consensus: $116.7M) and EPS of $0.71 to $0.74 (consensus: $0.78).</li><li>               Downside FY guidance has revenue from $393M to $396M (was: $399M to $404M; consensus: $404.3M) and EPS from $2.45 to $2.48 (was: $2.45 to $2.50; consensus: $2.50). &nbsp;&nbsp;</li><li>               Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"https://www.progress.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17284133-progress-reports-2018-third-quarter-results-announces-11-percent-dividend-increase\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393574-progress-software-beats-0_02-misses-revenue\" target=\"_blank\">Progress Software beats by $0.02, misses on revenue</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393572-progress-software-declares-0_155-dividend\" target=\"_blank\">Progress Software declares $0.155 dividend</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393581\" data-linked=\"Progress Software -13% on mixed Q3, downside Q4 and FY guides\" data-tweet=\"$PRGS - Progress Software -13% on mixed Q3, downside Q4 and FY guides https://seekingalpha.com/news/3393581-progress-softwareminus-13-on-mixed-q3-downside-q4-and-fy-guides?source=tweet\" data-url=\"https://seekingalpha.com/news/3393581-progress-softwareminus-13-on-mixed-q3-downside-q4-and-fy-guides\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393576\" data-ts=\"1538079544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393576-calampplus-2_3-on-q2-beats-in-line-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp +2.3% on Q2 beats, in-line guide</a></h4><ul><li>        CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>)&nbsp;<font color='green'>gains 2.3%</font>&nbsp;aftermarket on Q2 beats with a 7% Y/Y revenue growth. In-line Q3 guidance has revenue of $94M to $99M (consensus: $98.53M) and EPS of $0.29 to $0.35 (consensus: $0.32).</li><li>               Revenue breakdown: Telematics Systems, $77.1M (+37% Y/Y); Software &amp; Subscription Services, $18.9M (+21%).&nbsp;</li><li>                  Operating cash flow was $5.9M with adjusted EBITDA of $13.7M.    </li><li>               Earnings call is scheduled for 4:30 PM ET with a webcast available <a href=\"http://www.calamp.com/\" target=\"_blank\">here.</a>&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17284105-calamp-reports-fiscal-2019-second-quarter-financial-results\" target=\"_blank\">Press release.</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393564-calamp-beats-0_03-beats-revenue\" target=\"_blank\">CalAmp beats by $0.03, beats on revenue</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393576\" data-linked=\"CalAmp +2.3% on Q2 beats, in-line guide\" data-tweet=\"$CAMP - CalAmp +2.3% on Q2 beats, in-line guide https://seekingalpha.com/news/3393576-calampplus-2_3-on-q2-beats-in-line-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3393576-calampplus-2_3-on-q2-beats-in-line-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393575\" data-ts=\"1538079491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393575-fda-oks-adamis-pharmas-low-dose-symjepi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Adamis Pharma&#39;s low-dose Symjepi</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17284091-adamis-pharmaceuticals-receives-fda-approval-lower-dose-symjepi-product\" target=\"_blank\">approves </a>Adamis Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a>) lower-dose version (0.15 mg) of emergency allergic reaction med Symjepi (epinephrine) for pediatric use.</li><li>Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) unit Sandoz will commercialize.</li><li>ADMP will resume trading at 4:25 pm ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385900-adamis-pharma-expects-fda-nod-low-dose-symjepi\" target=\"_blank\">Adamis Pharma expects FDA nod for low-dose Symjepi</a> (Aug. 27)</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>6%</font>&nbsp;after the resumption of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393575\" data-linked=\"FDA OKs Adamis Pharma&#39;s low-dose Symjepi\" data-tweet=\"$ADMP $ADMP $NVS - FDA OKs Adamis Pharma&#39;s low-dose Symjepi https://seekingalpha.com/news/3393575-fda-oks-adamis-pharmas-low-dose-symjepi?source=tweet\" data-url=\"https://seekingalpha.com/news/3393575-fda-oks-adamis-pharmas-low-dose-symjepi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393570\" data-ts=\"1538079037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPRO\" target=\"_blank\">SPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393570-spero-therapeutics-to-advance-antibiotic-candidate-spr994-2x-higher-dose-shares-up-11-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spero Therapeutics to advance antibiotic candidate SPR994 at 2x higher dose; shares up 11% after hours</a></h4><ul><li>Based on a <a href=\"https://seekingalpha.com/pr/17284074-spero-announces-positive-spr994-phase-1-sad-mad-final-results\" target=\"_blank\">final analysis</a> of a Phase 1 clinical trial trial, Spero Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SPRO' title='Spero Therapeutics, Inc.'>SPRO</a>) will advance oral antibiotic candidate SPR994 into Phase 3 development at at dose of 600 mg, twice the level originally planned. Data from healthy volunteers showed greater drug exposure with the higher dose with a favorable safety profile.</li><li>The Phase 3 study should launch by year-end.</li><li>Shares are up&nbsp;<font color='green'>11%</font>&nbsp;after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3368550-spero-10-percent-premarket-positive-early-stage-data-oral-antibiotic-spr994\" target=\"_blank\">Spero up 10% premarket on positive early-stage data on oral antibiotic SPR994</a> (July 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393570\" data-linked=\"Spero Therapeutics to advance antibiotic candidate SPR994 at 2x higher dose; shares up 11% after hours\" data-tweet=\"$SPRO - Spero Therapeutics to advance antibiotic candidate SPR994 at 2x higher dose; shares up 11% after hours https://seekingalpha.com/news/3393570-spero-therapeutics-to-advance-antibiotic-candidate-spr994-2x-higher-dose-shares-up-11-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3393570-spero-therapeutics-to-advance-antibiotic-candidate-spr994-2x-higher-dose-shares-up-11-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393564\" data-ts=\"1538078784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393564-calamp-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp beats by $0.03, beats on revenue</a></h4><ul><li>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>): Q2 Non-GAAP EPS of $0.31 <span style=\"color:green\">beats by $0.03</span>; GAAP EPS of -$0.02.</li><li>Revenue of $96.04M (+7.0% Y/Y) <font color='green'>beats by $0.68M</font>.</li><li>Shares <font color='green'>+2.5%</font>.</li><li><a href='https://seekingalpha.com/pr/17284105-calamp-reports-fiscal-2019-second-quarter-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3393564\" data-linked=\"CalAmp beats by $0.03, beats on revenue\" data-tweet=\"$CAMP - CalAmp beats by $0.03, beats on revenue https://seekingalpha.com/news/3393564-calamp-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3393564-calamp-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393562\" data-ts=\"1538078674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393562-teslaminus-6-on-report-of-sec-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla -6% on report of SEC action</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) CEO Elon Musk has been sued by the SEC, according to a Bloomberg headline.</li><li>The lawsuit was filed in federal court in Manhattan.</li><li>The story is developing. Updates will be posted.</li>  <li>Shares of Tesla are <font color='red'>down 6%</font> in AH trading.</li><li><strong>Updated 4:17 p.m. -</strong>&nbsp;The court docket indicates that Tesla has also been sued by the regulator. CNBC reports the lawsuit alleges fraud against both Musk and Tesla.</li><li><strong>Updated 4:20 p.m</strong>. - The SEC states that Musk \"falsely\" claimed he could take Tesla private. TSLA is&nbsp;<font color='red'>down 5.7%</font>&nbsp;in heavy AH action.</li><li><strong>Updated 4:39 p.m</strong>. - The SEC plans to hold a news conference at 5:00 p.m.</li><li><strong>Updated 4:58 p.m</strong>. - The SEC action asks for a permanent ban on Elon Musk serving as an officer or director at public company. The SEC complaint does not name Tesla as indicated in earlier reports.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3393562\" data-linked=\"Tesla -6% on report of SEC action\" data-tweet=\"$TSLA - Tesla -6% on report of SEC action https://seekingalpha.com/news/3393562-teslaminus-6-on-report-of-sec-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3393562-teslaminus-6-on-report-of-sec-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>383&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393551\" data-ts=\"1538076229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRM\" target=\"_blank\">CRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393551-bmo-out-positive-on-salesforce-after-dreamforce-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BMO out positive on Salesforce after Dreamforce event</a></h4><ul><li>        BMO is out positive on Salesforce (NYSE:<a href='https://seekingalpha.com/symbol/CRM' title='Salesforce.com, Inc.'>CRM</a>) after the Dreamforce event.</li><li>                  Analyst Keith Bachman said the event renewed conviction that Salesforce can sustain 20% revenue growth and the company deserves its top pick designation in software.    </li><li>               Bachman remains bullish on the long-term potential of Customer 360 and is warming up to the MuleSoft buy after detecting &ldquo;a lot of customer enthusiasm&rdquo; with management indicating ASPs are +30% since the deal closed.&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;</li><li>               Salesforce shares are<font color='green'> up 1.4%&nbsp;</font>to $160.56.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393551\" data-linked=\"BMO out positive on Salesforce after Dreamforce event\" data-tweet=\"$CRM - BMO out positive on Salesforce after Dreamforce event https://seekingalpha.com/news/3393551-bmo-out-positive-on-salesforce-after-dreamforce-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3393551-bmo-out-positive-on-salesforce-after-dreamforce-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393541\" data-ts=\"1538074579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JRJC\" target=\"_blank\">JRJC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393541-technology-top-5-gainers-losers-of-2_55-pm-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (09/27/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a> <font color='green'>+8%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile'>JG</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-8%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3393541\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (09/27/2018)\" data-tweet=\"$JRJC $JRJC $MTSL - Technology - Top 5 Gainers / Losers as of 2.55 PM (09/27/2018) https://seekingalpha.com/news/3393541-technology-top-5-gainers-losers-of-2_55-pm-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393541-technology-top-5-gainers-losers-of-2_55-pm-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393540\" data-ts=\"1538073589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGP\" target=\"_blank\">FGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393540-ferrellgas-ceo-says-working-to-address-capital-structure-sharesminus-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ferrellgas CEO says working to address capital structure; shares -18%</a></h4><ul><li>Ferrellgas Partners (<a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners L.P'>FGP</a> <font color='red'>-15.6%</font>) plunges as much as 26% to a record low after <a href=\"https://seekingalpha.com/news/3393457-ferrellgas-partners-q4-results\" target=\"_blank\">Q4 adjusted EBITDA declines 210 bps</a> to 2.3% and missing the lowest analyst estimate.</li><li>Interim CEO Jim Ferrell said on today's earnings call that FGP needs to address its capital structure and is working on it although not via \"short term band-aids,\" saying the company is focused on long-term solutions even if it affects the distribution.</li><li>Ferrell said FGP would not do anything that does not benefit the long-term viability of the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393540\" data-linked=\"Ferrellgas CEO says working to address capital structure; shares -18%\" data-tweet=\"$FGP - Ferrellgas CEO says working to address capital structure; shares -18% https://seekingalpha.com/news/3393540-ferrellgas-ceo-says-working-to-address-capital-structure-sharesminus-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3393540-ferrellgas-ceo-says-working-to-address-capital-structure-sharesminus-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393539\" data-ts=\"1538073552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLI\" target=\"_blank\">CLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393539-mack-cali-jumps-4-activist-claims-buyout-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mack-Cali jumps 4% as activist claims buyout interest</a></h4><ul><li>Mack-Cali (<a href='https://seekingalpha.com/symbol/CLI' title='Mack-Cali Realty Corp.'>CLI</a> <font color='green'>+4.1%</font>) has received <a href=\"https://www.bloomberg.com/news/articles/2018-09-27/litt-says-mack-cali-may-have-turned-away-unidentified-suitor\" target=\"_blank\">a letter indicating interest</a> in a fully-financed bid, according to Jonathan Litt.</li><li>Litt's Land &amp; Buildings owns more than 2% of Mack-Cali, and is pushing for changes or a sale.</li><li>Litt: \"The indication of interest appears to be at a valuation (and with financing) which would be attractive for the full board of directors to evaluate and not dismissed out of hand as it may have been.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393539\" data-linked=\"Mack-Cali jumps 4% as activist claims buyout interest\" data-tweet=\"$CLI - Mack-Cali jumps 4% as activist claims buyout interest https://seekingalpha.com/news/3393539-mack-cali-jumps-4-activist-claims-buyout-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3393539-mack-cali-jumps-4-activist-claims-buyout-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393533\" data-ts=\"1538071224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGC\" target=\"_blank\">IGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393533-energy-materials-top-5-gainers-losers-of-2-00-pm-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top 5 Gainers / Losers as of 2:00 PM (09/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners L.P'>FGP</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FUL' title='H.B. Fuller Company'>FUL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393533\" data-linked=\"Energy/Materials  - Top 5 Gainers / Losers as of 2:00 PM (09/27/2018)\" data-tweet=\"$IGC $IGC $GBR - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (09/27/2018) https://seekingalpha.com/news/3393533-energy-materials-top-5-gainers-losers-of-2-00-pm-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393533-energy-materials-top-5-gainers-losers-of-2-00-pm-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393531\" data-ts=\"1538070249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393531-stifel-raises-amazon-to-street-high-target-implying-1_23t-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel raises Amazon to Street-high target implying $1.23T valuation</a></h4><ul><li>        Stifel <a href=\"https://www.cnbc.com/2018/09/27/stifel-issues-street-high-amazon-price-target-sees-27-percent-upside.html\" target=\"_blank\">gives</a> Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) the new Street-high price target of $2,525, a 27% upside implying a $1.23T valuation.</li><li>               Analyst Scott Devitt says the firm supports &ldquo;where Amazon&rsquo;s investment dollars are focused as we believe this better positions the company for continued market share gains.&rdquo; Cited investment areas included Prime, AWS, India, logistics, video content, and Alexa. &nbsp;&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 2%</font>&nbsp;to $2,013.50.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387610-amazon-hits-1t-market-cap\" target=\"_blank\">Amazon hits $1T market cap</a> (Sept. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392782-jefferies-amazon-hit-1_5t-2020\" target=\"_blank\">Jefferies: Amazon could hit $1.5T by 2020</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393531\" data-linked=\"Stifel raises Amazon to Street-high target implying $1.23T valuation\" data-tweet=\"$AMZN - Stifel raises Amazon to Street-high target implying $1.23T valuation https://seekingalpha.com/news/3393531-stifel-raises-amazon-to-street-high-target-implying-1_23t-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3393531-stifel-raises-amazon-to-street-high-target-implying-1_23t-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393530\" data-ts=\"1538070171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393530-adamis-pharma-shares-halted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis Pharma shares halted</a></h4><ul><li>Nasdaq has suspended trading in Adamis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a>) pending the release of news, almost a certainty that it is related to the expected FDA approval of low-dose Symjepi.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393530\" data-linked=\"Adamis Pharma shares halted\" data-tweet=\"$ADMP - Adamis Pharma shares halted https://seekingalpha.com/news/3393530-adamis-pharma-shares-halted?source=tweet\" data-url=\"https://seekingalpha.com/news/3393530-adamis-pharma-shares-halted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393526\" data-ts=\"1538069378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLCF\" target=\"_blank\">SOLCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393526-scythian-completes-sale-of-latin-american-assets-to-aphria-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scythian completes sale of Latin American assets to Aphria; shares up 5%</a></h4><ul><li>Scythian Biosciences (SCCYF <font color='green'>+5.3%</font>) has <a href=\"https://seekingalpha.com/pr/17283796-scythian-biosciences-closes-strategic-sale-latin-american-caribbean-assets\" target=\"_blank\">closed the sale</a> of its Latin American assets, 100% of the outstanding shares in shares of subsidiary LATAM Holdings, to Aphria.</li><li>Under the terms of the deal, Scythian received ~15.7M shares of Aphria stock while Aphria assumed $1M in Scythian liabilities. 350K of the shares will be held back until Scythian satisfies a $5M obligation to Colcanna SAS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393526\" data-linked=\"Scythian completes sale of Latin American assets to Aphria; shares up 5%\" data-tweet=\"$SOLCF - Scythian completes sale of Latin American assets to Aphria; shares up 5% https://seekingalpha.com/news/3393526-scythian-completes-sale-of-latin-american-assets-to-aphria-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3393526-scythian-completes-sale-of-latin-american-assets-to-aphria-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393525\" data-ts=\"1538069251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393525-facebook-gains-on-dau-metrics-admits-to-phone-number-ad-targeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook gains on DAU metrics, admits to phone number ad targeting</a></h4><ul><li>        Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) shares&nbsp;<font color='green'>gain 2.5%</font>&nbsp;today after the company&rsquo;s <a href=\"https://www.theverge.com/2018/9/26/17905348/facebook-stories-messenger-daily-active-users\" target=\"_blank\">metric reveal</a> yesterday that there&rsquo;s now a combined 300M DAUs across Facebook Stories and Messenger.</li><li>               The number gains on Messenger&rsquo;s 70M DAUs revealed this time last year. Stories had 150M DAUs in May. The services combined had at least 220M daily active users as of last May.&nbsp;</li><li>               In Snap&rsquo;s most recent earnings report, the company revealed Snapchat&rsquo;s DAUs shrank from 191M to 188M Q/Q. &nbsp;&nbsp;&nbsp;</li><li>               The metrics announcement came as Facebook opened up Stories to advertisers. The news also broke around the same time Gizmodo reported on the fact that Facebook uses the phone numbers it collects for two-factor authentication to target ads at users.&nbsp;</li><li>               Today, Facebook<a href=\"https://techcrunch.com/2018/09/27/yes-facebook-is-using-your-2fa-phone-number-to-target-you-with-ads/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\"> admitted</a> to the ad targeting and says users can opt out by not using a phone number for two-factor authentication and deleting the one already on file, if relevant.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392858-without-co-founders-instagram-likely-see-tighter-ties-parent-facebook\" target=\"_blank\">Without co-founders, Instagram likely to see tighter ties to parent Facebook</a> (Sept. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393184-oculus-launch-new-quest-wireless-headset-spring-399\" target=\"_blank\">Oculus to launch new Quest wireless headset in spring for $399</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393525\" data-linked=\"Facebook gains on DAU metrics, admits to phone number ad targeting\" data-tweet=\"$FB - Facebook gains on DAU metrics, admits to phone number ad targeting https://seekingalpha.com/news/3393525-facebook-gains-on-dau-metrics-admits-to-phone-number-ad-targeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3393525-facebook-gains-on-dau-metrics-admits-to-phone-number-ad-targeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393519\" data-ts=\"1538068061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393519-wells-fargo-defends-cruise-line-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo defends cruise line stocks</a></h4><ul> <li>Wells Fargo is positive on the cruise line sector amid a tough day for Carnival (<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a> <font color='red'>-5.2%</font>), Royal Caribbean (<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a> <font color='red'>-0.2%</font>) and Norwegian Cruise Line Holdings (<a href='https://seekingalpha.com/symbol/NCLH' title='Norwegian Cruise Line Holdings Ltd.'>NCLH</a> <font color='red'>-0.8%</font>) following weak Carnival guidance.</li> <li>The firm is Overweight the cruise line sector as a whole on its view that global net cruise industry capacity will grow 5% over the next five years.</li> <li>WF: \"We believe the global cruise industry is at a remote risk from global trade/tariff tensions. This coupled with (1) attractive valuations relative to other consumer discretionary sectors (most with arguably more trade/tariff exposure), (2) minimal 2018 hurricane impacts, and (3) solid demand trends through H119 have begun (and should continue post Q318 earnings) to upwardly re-rate the group.\"</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3393406-carnival-beats-0_04-beats-revenue\" target=\"_blank\">Carnival beats by $0.04, beats on revenue</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393451-cruise-line-sector-trades-weak-carnival-guidance-disappoints\" target=\"_blank\">Cruise line sector trades weak after Carnival guidance disappoints</a> (Sept. 27)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3393519\" data-linked=\"Wells Fargo defends cruise line stocks\" data-tweet=\"$CCL $CCL $RCL - Wells Fargo defends cruise line stocks https://seekingalpha.com/news/3393519-wells-fargo-defends-cruise-line-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3393519-wells-fargo-defends-cruise-line-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393518\" data-ts=\"1538067908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRUP\" target=\"_blank\">TRUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393518-financials-top-5-gainers-losers-of-1-05-pm-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:05 PM (09/27/2018)</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/TRUP' title='Trupanion'>TRUP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GSHD' title='Goosehead Insurance'>GSHD</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+5%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393518\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:05 PM (09/27/2018)\" data-tweet=\"$TRUP $TRUP $OXBR - Financials - Top 5 Gainers / Losers as of 1:05 PM (09/27/2018) https://seekingalpha.com/news/3393518-financials-top-5-gainers-losers-of-1-05-pm-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393518-financials-top-5-gainers-losers-of-1-05-pm-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393512\" data-ts=\"1538066442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHV\" target=\"_blank\">ACHV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393512-midday-gainers-losers-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (09/27/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='green'>+58%</font>. RXII <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/HAIR' title='Restoration Robotics'>HAIR</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics'>NTGN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies'>LQDA</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+16%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='red'>-63%</font>. <a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx'>CCXI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CDTI' title='Clean Diesel Technologies, Inc.'>OTC:CDTI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TPNL' title='3Pea International, Inc.'>TPNL</a> <font color='red'>-12%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3393512\" data-linked=\"Midday Gainers / Losers (09/27/2018)\" data-tweet=\"$ACHV $ACHV $PHIO - Midday Gainers / Losers (09/27/2018) https://seekingalpha.com/news/3393512-midday-gainers-losers-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393512-midday-gainers-losers-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393511\" data-ts=\"1538066259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEO\" target=\"_blank\">CEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393511-chinas-cnooc-says-may-divest-not-all-u-s-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China&#39;s Cnooc says may divest some but not all U.S. assets</a></h4><ul>     <li>China's Cnooc (<a href='https://seekingalpha.com/symbol/CEO' title='CNOOC Limited'>CEO</a> <font color='green'>+3.2%</font>) says it is <a href=\"https://www.reuters.com/article/us-cnooc-oil-usa-nexen/chinas-cnooc-may-divest-some-u-s-assets-after-portfolio-review-idUSKCN1M70OM\" target=\"_blank\">considering selling some of its U.S. oil assets</a> in the Gulf of Mexico following a portfolio review but that it does not intend to fully exit the U.S. market.</li>     <li>Cnooc unit Nexen Petroleum was planning to exit the U.S., according to a <a href=\"https://www.reuters.com/article/us-nexen-energy-m-a-oil-exclusive/exclusive-chinas-nexen-plans-gulf-of-mexico-oil-exit-amid-trade-war-sources-idUSKCN1M631R\" target=\"_blank\">Reuters report</a>, divesting its stake in major oil and gas developments in the Gulf of Mexico amid the U.S.-China trade dispute.</li>     <li>Cnooc says it has no plan to divest stakes in producing oil assets in the Gulf of Mexico, which includes a 25% stake in Hess' (NYSE:<a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a>) Stampede development and a 21% interest in Shell&rsquo;s (<a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a>, <a href='https://seekingalpha.com/symbol/RDS.B' title='Royal Dutch Shell plc'>RDS.B</a>) Appomattox development.</li>     <li>&ldquo;We just had a review of the company&rsquo;s growing global assets... the Guyana discovery is redefining our perspective,&rdquo; says a Cnooc spokesperson, referring to the large oil discovery at the Stabroek block offshore Guyana where it partners with Exxon which could recover more than 4B barrels of oil.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393511\" data-linked=\"China&#39;s Cnooc says may divest some but not all U.S. assets\" data-tweet=\"$CEO $CEO $HES - China&#39;s Cnooc says may divest some but not all U.S. assets https://seekingalpha.com/news/3393511-chinas-cnooc-says-may-divest-not-all-u-s-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3393511-chinas-cnooc-says-may-divest-not-all-u-s-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393508\" data-ts=\"1538065141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHL\" target=\"_blank\">CHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393508-china-mobile-under-antitrust-probe-capitol-forum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Mobile under antitrust probe - Capitol Forum</a></h4><ul><li><a href=\"https://thecapitolforum.com/\" target=\"_blank\">According to Capitol Forum</a>, China Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CHL' title='China Mobile Limited'>CHL</a>) is under investigation by China's State Administration for Market Regulation over \"market domination.\"</li><li>The ADRs have dipped a bit on the news, now&nbsp;<font color='red'>down 0.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393508\" data-linked=\"China Mobile under antitrust probe - Capitol Forum\" data-tweet=\"$CHL - China Mobile under antitrust probe - Capitol Forum https://seekingalpha.com/news/3393508-china-mobile-under-antitrust-probe-capitol-forum?source=tweet\" data-url=\"https://seekingalpha.com/news/3393508-china-mobile-under-antitrust-probe-capitol-forum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393507\" data-ts=\"1538064973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393507-insurers-managed-care-providers-in-green-cvs-aetna-tie-up-nears-finish-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insurers/managed care providers in the green as CVS/Aetna tie-up nears finish line</a></h4><ul><li>The broad market's up day notwithstanding, health insurers and managed care providers are enjoying increased buying as the expected green light for the CVS Health/Aetna merger approaches. Regulators are also expected to give a thumbs up to the Cigna/Express Scripts tie-up.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='green'>+4.3%</font>)(<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+4.2%</font>)(<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a> <font color='green'>+2.3%</font>)(<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='green'>+1.7%</font>)(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+1.3%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color='green'>+1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393507\" data-linked=\"Insurers/managed care providers in the green as CVS/Aetna tie-up nears finish line\" data-tweet=\"$HIIQ $HIIQ $WCG - Insurers/managed care providers in the green as CVS/Aetna tie-up nears finish line https://seekingalpha.com/news/3393507-insurers-managed-care-providers-in-green-cvs-aetna-tie-up-nears-finish-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3393507-insurers-managed-care-providers-in-green-cvs-aetna-tie-up-nears-finish-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393506\" data-ts=\"1538064887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYR\" target=\"_blank\">AYR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393506-aircastleplus-5-after-cowen-upgrades-gives-street-high-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aircastle +5% after Cowen upgrades, gives Street-high price target</a></h4><ul>     <li>Aircastle (<a href='https://seekingalpha.com/symbol/AYR' title='Aircastle Limited'>AYR</a> <font color='green'>+5.1%</font>)&nbsp;surges as much as 6% after Cowen <a href=\"https://www.streetinsider.com/Analyst+Comments/Cowen+Upgrades+Aircastle+Limited+%28AYR%29+to+Outperform/14648501.html\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with a price target raised to a Street-high $26 from $24.</li>     <li>The commercial jet leasing company has been able to grow because of its borrowing capacity and ability to acquire quality used jets, a strategy that limits AYR&rsquo;s risk in case of downturn and positions it well for improved earnings growth, Cowen analyst Helane Becker says.</li>     <li>AYR was upgraded to investment grade by S&amp;P Global, Fitch and Moody&rsquo;s earlier this year, achieving an important management goal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393506\" data-linked=\"Aircastle +5% after Cowen upgrades, gives Street-high price target\" data-tweet=\"$AYR - Aircastle +5% after Cowen upgrades, gives Street-high price target https://seekingalpha.com/news/3393506-aircastleplus-5-after-cowen-upgrades-gives-street-high-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3393506-aircastleplus-5-after-cowen-upgrades-gives-street-high-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393498\" data-ts=\"1538064229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELTK\" target=\"_blank\">ELTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393498-eltek-down-2-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eltek down 2% post Q2 results</a></h4><ul><li>Eltek (<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='red'>-2%</font>) reported Q2 revenue growth of 15.8% Y/Y to $8.67M, and gross profit of $578k compared to $134k a year ago.</li><li>Q2 Gross margin&nbsp;<font color='green'>improved by 488 bps</font>&nbsp;to 6.7%; operating margin&nbsp;<font color='green'>recovered by 528 bps</font>&nbsp;to -8.3% and Adj. EBITDA margin&nbsp;<font color='green'>recovered by 437 bps</font>&nbsp;to -3.4%</li><li>SG&amp;A expenses increased by 14.2% Y/Y to $1.3M.</li><li>Inventories were $4.55M (+5.8% Y/Y) as of June 30, 2018.</li><li>Net cash used in operating activities was $571k compared to $517k a year ago. Company has cash and cash equivalents of $991k as of June 30, 2018.</li><li>Eltek appointed Mr. Eli Yaffe, as the CEO, he has a proven track record as a CEO in the defense and aerospace industries.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393319-eltek-reports-q2-results\" target=\"_blank\">Eltek reports Q2 results</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393498\" data-linked=\"Eltek down 2% post Q2 results\" data-tweet=\"$ELTK - Eltek down 2% post Q2 results https://seekingalpha.com/news/3393498-eltek-down-2-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3393498-eltek-down-2-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393497\" data-ts=\"1538064057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YGYI\" target=\"_blank\">YGYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393497-consumer-top-gainers-losers-of-12-00-pm-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (09/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/COT' title='Cott Corporation'>COT</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SANW' title='S&W Seed Co'>SANW</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393497\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (09/27/2018)\" data-tweet=\"$YGYI $YGYI $COT - Consumer - Top Gainers / Losers as of 12:00 PM (09/27/2018) https://seekingalpha.com/news/3393497-consumer-top-gainers-losers-of-12-00-pm-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393497-consumer-top-gainers-losers-of-12-00-pm-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393494\" data-ts=\"1538063709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVS\" target=\"_blank\">CVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393494-aetna-to-sell-medicare-part-d-business-to-wellcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aetna to sell Medicare Part D business to WellCare</a></h4><ul><li>Aimed at getting a thumbs up from antitrust watchdogs for its planned takeover by CVS Health (<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color='green'>+1%</font>), Aetna (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+0.8%</font>) has <a href=\"https://www.wsj.com/articles/aetna-to-sell-medicare-prescription-drug-business-to-wellcare-health-1538049568\" target=\"_blank\">agreed to sell</a> its Medicare Part D prescription business to WellCare Health Plans (<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+4.2%</font>).</li><li>The transaction is dependent on the consummation of the CVS/Aetna tie-up.</li><li>Financial details are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393494\" data-linked=\"Aetna to sell Medicare Part D business to WellCare\" data-tweet=\"$CVS $CVS $AET - Aetna to sell Medicare Part D business to WellCare https://seekingalpha.com/news/3393494-aetna-to-sell-medicare-part-d-business-to-wellcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3393494-aetna-to-sell-medicare-part-d-business-to-wellcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393489\" data-ts=\"1538063186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYEKF\" target=\"_blank\">TYEKF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393489-thyssenkrupp-to-split-two-companies-succumbing-to-activist-pressure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thyssenkrupp to split into two companies, succumbing to activist pressure</a></h4><ul>     <li>Thyssenkrupp (<a href='https://seekingalpha.com/symbol/TYEKF' title='ThyssenKrupp AG'>OTCPK:TYEKF</a> <font color='green'>+8.1%</font>) is <a href=\"https://www.reuters.com/article/us-thyssenkrupp-restructuring-exclusive/thyssenkrupp-to-spin-off-elevators-car-parts-in-major-group-overhaul-idUSKCN1M71HV\" target=\"_blank\">planning to split into two companies</a>, spinning off its elevators, car parts and plant engineering divisions, in the company's biggest overhaul since the merger of Thyssen and Krupp 20 years ago.</li>     <li>The plan is a victory for activist shareholders Cevian and Elliott, which have demanded concrete structural measures to improve the company&rsquo;s operational performance blamed on its sprawling conglomerate structure.</li>     <li>Thyssenkrupp&rsquo;s supervisory board is expected to sign off on the plans at a special meeting on Sunday, Sept. 30, which also marks the end of the company&rsquo;s financial year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393489\" data-linked=\"Thyssenkrupp to split into two companies, succumbing to activist pressure\" data-tweet=\"$TYEKF - Thyssenkrupp to split into two companies, succumbing to activist pressure https://seekingalpha.com/news/3393489-thyssenkrupp-to-split-two-companies-succumbing-to-activist-pressure?source=tweet\" data-url=\"https://seekingalpha.com/news/3393489-thyssenkrupp-to-split-two-companies-succumbing-to-activist-pressure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393486\" data-ts=\"1538063023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UROV\" target=\"_blank\">UROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393486-urovant-sciences-limps-out-of-gate-down-25-from-14-ipo-price\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urovant Sciences limps out of the gate, down 25% from $14 IPO price</a></h4><ul><li>Urovant Sciences (<a href='https://seekingalpha.com/symbol/UROV' title='Urovant Sciences'>UROV</a> <font color='red'>N/A</font>) has debuted weakly. Shares are currently exchanging hands at $10.57, down&nbsp;<font color='red'>25%</font>&nbsp;from the IPO price of $14, the low end of its previously announced range of $14 - 16.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392848-urovant-sciences-sets-terms-ipo\" target=\"_blank\">Urovant Sciences sets terms for IPO</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393486\" data-linked=\"Urovant Sciences limps out of the gate, down 25% from $14 IPO price\" data-tweet=\"$UROV - Urovant Sciences limps out of the gate, down 25% from $14 IPO price https://seekingalpha.com/news/3393486-urovant-sciences-limps-out-of-gate-down-25-from-14-ipo-price?source=tweet\" data-url=\"https://seekingalpha.com/news/3393486-urovant-sciences-limps-out-of-gate-down-25-from-14-ipo-price\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393483\" data-ts=\"1538062232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIX\" target=\"_blank\">WIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393483-wixplus-2_6-on-suntrust-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wix +2.6% on SunTrust target boost</a></h4><ul><li>        SunTrust <a href=\"https://www.streetinsider.com/Analyst+Comments/Wix.com+%28WIX%29+PT+Raised+to+%24145+at+SunTrust+Robinson+Humphrey/14649339.htm\" target=\"_blank\">raises</a> its Wix (NASDAQ:<a href='https://seekingalpha.com/symbol/WIX' title='Wix.com'>WIX</a>) price target from $120 to $145 and maintains a Buy rating.</li><li>               Analyst Naved Khan cites Wix&rsquo;s &ldquo;large and growing user base&rdquo; that counted 131M as of Q2 and its &ldquo;best-in-class fermium offering and rising brand awareness&rdquo; as the competitive advantages allowing for above-market growth for the &ldquo;foreseeable future.&rdquo;&nbsp;</li><li>               Wix shares are&nbsp;<font color='green'>up 2.6%</font>&nbsp;to $118.83.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393483\" data-linked=\"Wix +2.6% on SunTrust target boost\" data-tweet=\"$WIX - Wix +2.6% on SunTrust target boost https://seekingalpha.com/news/3393483-wixplus-2_6-on-suntrust-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3393483-wixplus-2_6-on-suntrust-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393477\" data-ts=\"1538061332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LQDA\" target=\"_blank\">LQDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393477-liquidia-tech-adds-to-strong-debut-up-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Liquidia Tech adds to strong debut, up 13%</a></h4><ul><li>Recent IPO <a href=\"http://liquidia.com/about-liquidia/\" target=\"_blank\">Liquidia Technologies</a>&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies'>LQDA</a>) has been a big winner, up&nbsp;<font color='green'>155%</font>&nbsp;from its $11 offer price about two months ago.</li><li>It was recently&nbsp;<a href=\"https://seekingalpha.com/pr/17278098-liquidia-technologies-added-russell-2000-3000-microcap-indexes\" target=\"_blank\">added </a>to the Russell 2000, 3000 and Microcap Indexes.</li><li>The Morrisville, NC-based biopharmaceutical firm develops drugs based on its particle engineering platform called <a href=\"http://liquidia.com/print-technology/\" target=\"_blank\">PRINT</a>. Lead candidate is <a href=\"http://liquidia.com/pipeline/\" target=\"_blank\">LIQ861</a>, a dry powder formulation of treprostinil [United Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a>) Remodulin], that it says has an improved therapeutic profile. It is currently being investigated for the treatment of pulmonary arterial hypertension &#40;PAH&#41;.</li><li>Shares are up&nbsp;<font color='green'>13%</font>&nbsp;on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393477\" data-linked=\"Liquidia Tech adds to strong debut, up 13%\" data-tweet=\"$LQDA $LQDA $UTHR - Liquidia Tech adds to strong debut, up 13% https://seekingalpha.com/news/3393477-liquidia-tech-adds-to-strong-debut-up-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3393477-liquidia-tech-adds-to-strong-debut-up-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393472\" data-ts=\"1538060846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMC\" target=\"_blank\">VMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393472-vulcan-mineralsplus-2-jefferies-says-voters-support-gas-tax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vulcan Minerals +2% as Jefferies says voters support gas tax</a></h4><ul><li>Vulcan Materials (<a href='https://seekingalpha.com/symbol/VMC' title='Vulcan Materials Company'>VMC</a> <font color='green'>+2.2%</font>) moves higher after Jefferies analyst Philip Ng  says a new survey shows a majority of California voters  oppose repealing a gas tax increase, a positive for the company given  concerns that a repeal would lower growth expectations in the state.</li><li>Jefferies analyst Philip Ng, who rates VMC as a Buy with a $133 price target, says California has a geography that is expected to drive outsized  volume for the company, with the increased funding for transportation  infrastructure projects from Senate Bill-1.</li><li>The increased state-level funding, coupled with a favorable economic  backdrop, position California as one of the fastest growing  aggregates markets, and VMC is the only major player with exposure,  Ng says.</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3393472\" data-linked=\"Vulcan Minerals +2% as Jefferies says voters support gas tax\" data-tweet=\"$VMC - Vulcan Minerals +2% as Jefferies says voters support gas tax https://seekingalpha.com/news/3393472-vulcan-mineralsplus-2-jefferies-says-voters-support-gas-tax?source=tweet\" data-url=\"https://seekingalpha.com/news/3393472-vulcan-mineralsplus-2-jefferies-says-voters-support-gas-tax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393468\" data-ts=\"1538060454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393468-healthcare-top-5-gainers-losers-of-11-00-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/27/2018)</a></h4><ul><li><b>Gainers:</b> RXII <font color='green'>+54%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='red'>-64%</font>. <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx'>CCXI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='red'>-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393468\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/27/2018)\" data-tweet=\"$PHIO $PHIO $ACHV - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/27/2018) https://seekingalpha.com/news/3393468-healthcare-top-5-gainers-losers-of-11-00-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393468-healthcare-top-5-gainers-losers-of-11-00-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393464\" data-ts=\"1538059812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UUUU\" target=\"_blank\">UUUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393464-energy-fuelsplus-6-after-resuming-vanadium-production\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Fuels +6% after resuming vanadium production</a></h4><ul>     <li>Energy Fuels (<a href='https://seekingalpha.com/symbol/UUUU' title='Energy Fuels Inc'>UUUU</a> <font color='green'>+6%</font>) says it expects to <a href=\"https://seekingalpha.com/pr/17282865-energy-fuels-commencing-vanadium-production-testing-new-approaches-mining-tight-vanadium\" target=\"_blank\">resume vanadium production</a> at its White Mesa Mill in November and produce significant quantities of salable vanadium oxide by year-end 2018.</li>     <li>The White Mesa Mill in Utah currently is the only facility in the U.S. capable of processing conventional mined vanadium resources, and UUUU says it will be the only primary producer of vanadium oxide in North America.</li>     <li>UUUU says it is preparing to conduct a test-mining program that selectively targets high-grade vanadium oxide resources at its La Sal Complex of uranium and vanadium mines in Utah, with the goal of significantly raising productivity and mined grades and reducing mining costs per pound.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393464\" data-linked=\"Energy Fuels +6% after resuming vanadium production\" data-tweet=\"$UUUU - Energy Fuels +6% after resuming vanadium production https://seekingalpha.com/news/3393464-energy-fuelsplus-6-after-resuming-vanadium-production?source=tweet\" data-url=\"https://seekingalpha.com/news/3393464-energy-fuelsplus-6-after-resuming-vanadium-production\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393456\" data-ts=\"1538059612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FUL\" target=\"_blank\">FUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393456-h-b-fuller-down-6-post-q3-earnings-miss-lowers-fy18-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H.B. Fuller down 6% post Q3 earnings miss; lowers FY18 guidance</a></h4><ul><li>H.B. Fuller (<a href='https://seekingalpha.com/symbol/FUL' title='H.B. Fuller Company'>FUL</a> <font color='red'>-6.3%</font>) reported Q3 revenue growth of 36.8% Y/Y to $770M and organic growth of +4.8%, driven by sales growth in every segment.</li><li>Revenue by Segments: Americas Adhesives $282.49M (+22.3% Y/Y); EIMEA $182.02M (+32.5% Y/Y); Asia Pacific $65.94M (+4.7% Y/Y); Construction Adhesives $121.14M (+105% Y/Y) and Engineering Adhesives $118.51M (+63.4% Y/Y).</li><li>Q3 Overall margins: Gross&nbsp;<font color='green'>improved by 148 bps</font>&nbsp;to 28.2%; operating&nbsp;<font color='green'>improved by 210 bps</font>&nbsp;to 9.2% and Adj. EBITDA margin<font color='green'> improved by 251 bps</font>&nbsp;to 15.6%.</li><li>Adj. EBITDA margins for Segments: Americas Adhesives 18%&nbsp;<font color='green'>up by 270 bps;&nbsp;</font>EIMEA 10.5%&nbsp;<font color='red'>down by 170 bps</font>; Asia Pacific 10%&nbsp;<font color='green'>up by 100 bps</font>; Construction Adhesives 19.4%<font color='green'> up by 1,160 bps</font>&nbsp;and Engineering Adhesives 16.2%&nbsp;<font color='green'>up by 120 bps.</font></li><li>SG&amp;A expenses increased by 32.5% Y/Y to $146.07M.</li><li>Cash flow from operations of $84M, compared to $38M a year ago.</li><li>Company had cash on hand of $150M and total debt equal to $2,364M, of which ~70 % had a fixed interest rate.</li><li><strong>FY18 Guidance: </strong>EPS $3.05-3.20 (prior $3.15-3.40), lowers guidance to reflect unfavorable movement in foreign currency exchange rates.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393283-h-b-fuller-misses-0_04-misses-revenue\" target=\"_blank\">H.B. Fuller misses by $0.04, misses on revenue</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393456\" data-linked=\"H.B. Fuller down 6% post Q3 earnings miss; lowers FY18 guidance\" data-tweet=\"$FUL - H.B. Fuller down 6% post Q3 earnings miss; lowers FY18 guidance https://seekingalpha.com/news/3393456-h-b-fuller-down-6-post-q3-earnings-miss-lowers-fy18-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3393456-h-b-fuller-down-6-post-q3-earnings-miss-lowers-fy18-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393459\" data-ts=\"1538059316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393459-packaged-food-stocks-peel-back\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Packaged food stocks peel back</a></h4><ul> <li>Several packaged food stocks are weak at the knees after ConAgra Brands (<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a> <font color='red'>-5.8%</font>) and McCormick(<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a> <font color='red'>-2.5%</font>) delivery a double-whammy of disappointing earnings report to the sector.</li> <li>B&amp;G Foods (<a href='https://seekingalpha.com/symbol/BGS' title='B&G Foods, Inc.'>BGS</a> <font color='red'>-2.7%</font>), Kellogg (<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a> <font color='red'>-1.9%</font>), J.M. Smucker (<a href='https://seekingalpha.com/symbol/SJM' title='J. M. Smucker Company'>SJM</a> <font color='red'>-1.8%</font>), Campbell Soup (<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a> <font color='red'>-1.5%</font>) and Farmer Bros. (<a href='https://seekingalpha.com/symbol/FARM' title='Farmer Brothers Company'>FARM</a> <font color='red'>-1.1%</font>) are all showing morning losses.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3393370-conagra-brands-trades-weak-earnings\" target=\"_blank\">ConAgra Brands trades weak after earnings</a> (Sept. 27)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3393314-mccormick-revises-fy2018-guidance\" target=\"_blank\">McCormick revises FY2018 guidance</a> (Sept. 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393459\" data-linked=\"Packaged food stocks peel back\" data-tweet=\"$CAG $CAG $MKC - Packaged food stocks peel back https://seekingalpha.com/news/3393459-packaged-food-stocks-peel-back?source=tweet\" data-url=\"https://seekingalpha.com/news/3393459-packaged-food-stocks-peel-back\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393458\" data-ts=\"1538059273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRDM\" target=\"_blank\">IRDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393458-iridium-communicationsplus-2_9-on-aws-collab-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium Communications +2.9% on AWS collab service</a></h4><ul><li>        Iridium Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/IRDM' title='Iridium Communications Inc'>IRDM</a>) <a href=\"https://seekingalpha.com/pr/17283559-iridium-simplify-adoption-iot-solutions-beyond-cellular-coverage-amazon-web-services\" target=\"_blank\">joins</a> the Amazon Web Services Partner Network and has been collaborating with AWS on developing Iridium CloudConnect, a satellite cloud-based solution offering global coverage for IoT applications.</li><li>               The CloudConnect service will launch next year and will be available with AWS IoT.&nbsp;&nbsp;</li><li>               IRDM shares are&nbsp;<font color='green'>up 2.9%&nbsp;</font>to $21.05.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393458\" data-linked=\"Iridium Communications +2.9% on AWS collab service\" data-tweet=\"$IRDM - Iridium Communications +2.9% on AWS collab service https://seekingalpha.com/news/3393458-iridium-communicationsplus-2_9-on-aws-collab-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3393458-iridium-communicationsplus-2_9-on-aws-collab-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393455\" data-ts=\"1538058623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393455-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+46 Bcf</strong> vs. +64 Bcf consensus, +86 Bcf last week.</li><li>Futures&nbsp;<font color='green'>+1.48%&nbsp;</font>to $3.024.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3393455\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3393455-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3393455-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393454\" data-ts=\"1538058396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REED\" target=\"_blank\">REED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393454-beverage-sector-on-watch-after-m-development\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beverage sector on watch after M&amp;A development</a></h4><ul> <li>Reed's (NYSEMKT:<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>) is <font color='green'>up 1.6%</font> and Cott's (NYSE:<a href='https://seekingalpha.com/symbol/COT' title='Cott Corporation'>COT</a>) is <font color='green'>1.5% higher</font> after a M&amp;A move is announced in the beverage sector.</li> <li>Coca-Cola Bottling (NASDAQ:<a href='https://seekingalpha.com/symbol/COKE' title='Coca-Cola Consolidated, Inc.'>COKE</a>) and National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) are also <font color='green'>up 1.1%</font> on the day.</li> <li>It's a different story for cannabis play New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>), which is showing a&nbsp;<font color='red'>8.4% decline</font>&nbsp;in early trading.</li><li>M&amp;A has been a major topic in the beverage industry over the last 90 days.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393386-keurig-dr-pepper-acquires-core-nutrition\" target=\"_blank\">Keurig Dr Pepper acquires Core Nutrition</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393430-keurig-dr-pepper-looks-core-new-growth-channel\" target=\"_blank\">Keurig Dr Pepper looks to CORE for new growth channel</a> (Sept. 27)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3393454\" data-linked=\"Beverage sector on watch after M&amp;A development\" data-tweet=\"$REED $REED $COT - Beverage sector on watch after M&amp;A development https://seekingalpha.com/news/3393454-beverage-sector-on-watch-after-m-development?source=tweet\" data-url=\"https://seekingalpha.com/news/3393454-beverage-sector-on-watch-after-m-development\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393452\" data-ts=\"1538058274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393452-rxi-pharma-up-64\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharma up 64%</a></h4><ul><li>Thinly traded nano cap RXi Pharmaceuticals (RXII <font color='green'>+63.8%</font>) is up on almost a 9x surge in volume trying to break free of a downtrend that began in earnest after touching $6.76 on March 15.</li><li>About a month ago, it filed a <a href=\"https://seekingalpha.com/news/3387329-rxi-pharma-files-equity-offering\" target=\"_blank\">prospectus </a>for an equity offering.</li><li>At the end of June, it had $5.3M in cash and equivalents while operations consumed $3.8M in H1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393452\" data-linked=\"RXi Pharma up 64%\" data-tweet=\"$PHIO - RXi Pharma up 64% https://seekingalpha.com/news/3393452-rxi-pharma-up-64?source=tweet\" data-url=\"https://seekingalpha.com/news/3393452-rxi-pharma-up-64\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393451\" data-ts=\"1538058062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393451-cruise-line-sector-trades-weak-after-carnival-guidance-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cruise line sector trades weak after Carnival guidance disappoints</a></h4><ul> <li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>) is <font color='red'>down 8.0%</font> after guidance for the company's FQ4 fell short of expectations.</li> <li>Fresh guidance from Carnival is for full-year EPS of $4.21 to $4.25 vs. $4.15 to $4.25 prior view. The slight bump in profit guidance was a surprise after Carnival set a better outlook for fuel and F/X headwinds.</li> <li>\"Going forward, we remain on a path toward continued growth in earnings and returns, driven to a greater degree by capacity increases as we add more efficient ships, replacing less efficient capacity,\" notes CEO Arnold Donald.</li> <li>As is typically the case in the cruise line sector, peers are reacting to the Carnival update. Norwegian Cruise Line (NASDAQ:<a href='https://seekingalpha.com/symbol/NCLH' title='Norwegian Cruise Line Holdings Ltd.'>NCLH</a>) is <font color='red'>down 3.4%</font> and Royal Caribbean (NYSE:<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a>) is <font color='red'>off 2.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393406-carnival-beats-0_04-beats-revenue\" target=\"_blank\">Carnival beats by $0.04, beats on revenue</a> (Sept. 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393451\" data-linked=\"Cruise line sector trades weak after Carnival guidance disappoints\" data-tweet=\"$CCL $CCL $NCLH - Cruise line sector trades weak after Carnival guidance disappoints https://seekingalpha.com/news/3393451-cruise-line-sector-trades-weak-after-carnival-guidance-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3393451-cruise-line-sector-trades-weak-after-carnival-guidance-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393449\" data-ts=\"1538057805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPM\" target=\"_blank\">WPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393449-wheaton-precious-metalsplus-5-cameco-tax-ruling-seen-positive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wheaton Precious Metals +5% as Cameco tax ruling seen as a positive</a></h4><ul>     <li>Wheaton Precious Metals (<a href='https://seekingalpha.com/symbol/WPM' title='Wheaton Precious Metals Corp'>WPM</a> <font color='green'>+4.6%</font>) surges in early trading as Cameco&rsquo;s (<a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+16.5%</font>) <a href=\"https://seekingalpha.com/news/3393342-cameco-plus-16-percent-winning-canada-tax-dispute\" target=\"_blank\">favorable tax ruling</a> is seen creating enhanced opportunity for WPM&rsquo;s tax settlement.</li>     <li>Scotiabank analyst Trevor Turnbull says WPM has a very strong fact set and foresees a greater opportunity for a settlement in light of the CCJ outcome.</li>     <li>Turnbull notes the Canada Revenue Agency disputed aspects of CCJ&rsquo;s foreign subsidiary, whereas it has not made any issue of WPM&rsquo;s Cayman Island structure and subsidiary.</li><li>WPM's appeal of the CRA reassessment is scheduled to begin in mid-September 2019, with a ruling likely to take up to a year following the trial.</li>     <li>Source: Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393449\" data-linked=\"Wheaton Precious Metals +5% as Cameco tax ruling seen as a positive\" data-tweet=\"$WPM $WPM $CCJ - Wheaton Precious Metals +5% as Cameco tax ruling seen as a positive https://seekingalpha.com/news/3393449-wheaton-precious-metalsplus-5-cameco-tax-ruling-seen-positive?source=tweet\" data-url=\"https://seekingalpha.com/news/3393449-wheaton-precious-metalsplus-5-cameco-tax-ruling-seen-positive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393446\" data-ts=\"1538057580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DEST\" target=\"_blank\">DEST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393446-double-digit-rally-for-destination-maternity-after-refi-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Double-digit rally for Destination Maternity after refi deal</a></h4><ul> <li>Destination Maternity (NASDAQ:<a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a>) is <font color='green'>up 10.3%</font> after the company announced a refinancing deal with Bank of America.</li> <li>Shares of the retailer trade at a four-week high.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393302-destination-maternity-announces-new-five-year-76m-re-financing-bank-america\" target=\"_blank\">Destination Maternity announces a new five-year $76M re-financing with Bank of America</a> (Sept. 27)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3393446\" data-linked=\"Double-digit rally for Destination Maternity after refi deal\" data-tweet=\"$DEST - Double-digit rally for Destination Maternity after refi deal https://seekingalpha.com/news/3393446-double-digit-rally-for-destination-maternity-after-refi-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3393446-double-digit-rally-for-destination-maternity-after-refi-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393445\" data-ts=\"1538057445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYTG\" target=\"_blank\">PYTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393445-pyramidion-technology-signs-agreement-to-acquire-cbd-firm-nxgen-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pyramidion Technology signs agreement to acquire CBD firm NxGen Brands</a></h4><ul>     <li>Pyramidion Technology (<a href='https://seekingalpha.com/symbol/PYTG' title='Pyramidion Technology Group, Inc.'>OTCPK:PYTG</a> <font color='green'>+7%</font>) <a href=\"https://markets.businessinsider.com/news/stocks/pyramidion-technology-group-inc-otc-pytg-signs-definitive-agreement-to-acquire-cbd-firm-nxgen-brands-1027570250\" target=\"_blank\">announced</a> today the signing of the definitive agreement to acquire 100% of NxGen Brands, specialists in CBD (Cannabinoid) extracts and related products.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386072-pyramidion-technology-group-signs-loi-acquire-nxgen-brands-llc\" target=\"_blank\">Pyramidion Technology Group signs LOI to acquire NxGen Brands, LLC</a> (Aug. 28)</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3393445\" data-linked=\"Pyramidion Technology signs agreement to acquire CBD firm NxGen Brands\" data-tweet=\"$PYTG - Pyramidion Technology signs agreement to acquire CBD firm NxGen Brands https://seekingalpha.com/news/3393445-pyramidion-technology-signs-agreement-to-acquire-cbd-firm-nxgen-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3393445-pyramidion-technology-signs-agreement-to-acquire-cbd-firm-nxgen-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393443\" data-ts=\"1538057333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHL\" target=\"_blank\">SCHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393443-scholastic-up-2_4-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scholastic up 2.4% post Q1 results</a></h4><ul><li>Scholastic (<a href='https://seekingalpha.com/symbol/SCHL' title='Scholastic Corporation'>SCHL</a> <font color='green'>+2.4%</font>) <a href=\"https://seekingalpha.com/pr/17282969-scholastic-reports-fiscal-2019-first-quarter-results\" target=\"_blank\">reports Q1</a> revenue of $218.4M (+15.4% Y/Y).</li><li>Revenue by segment: Children's book publishing and distribution, $93.3M (+40% Y/Y); Education, $50.3M (+12% Y/Y); International of $74.8M (-3% Y/Y).</li><li>Q1 Operating loss was $83.8M, an improvement compared to loss of $101.8M Y/Y whereas; adj. operating loss was $83.3M, an 11% improvement Y/Y.</li><li>Cash from operations was $89M; free cash use was $125.9M vs. prior year free cash flow of $131M.</li><li><strong>2019 Outlook:</strong> Revenues of $1.65-1.70B; Adj. EPS of $1.60-1.70; Adj. EBITDA $160-170M &amp; capital expenditures of $70-80M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393328-scholastic-beats-0_19-beats-revenue\" target=\"_blank\">Scholastic beats by $0.19, beats on revenue</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393443\" data-linked=\"Scholastic up 2.4% post Q1 results\" data-tweet=\"$SCHL - Scholastic up 2.4% post Q1 results https://seekingalpha.com/news/3393443-scholastic-up-2_4-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3393443-scholastic-up-2_4-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393442\" data-ts=\"1538057222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSET\" target=\"_blank\">BSET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393442-on-bassett-furnitures-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Bassett Furniture&#39;s Q3 results</a></h4><ul><li>Bassett Furniture (<a href='https://seekingalpha.com/symbol/BSET' title='Bassett Furniture Industries, Incorporated'>BSET</a> <font color='red'>-2.5%</font>)&nbsp;reports comparable-store sales fell 1.7% in <a href=\"https://seekingalpha.com/pr/17283401-bassett-announces-fiscal-third-quarter-results\" target=\"_blank\">Q3</a>.</li><li>Wholesale segment revenue increased 3.4% to $63.8M.</li><li>Retail segment revenue decreased 2.9% to $65.4M.</li><li>Logistical services revenue down 5.6% to $23.5M.</li><li>Gross margin rate flat at 60.3%.</li><li>Operating margin rate slipped 260 bps to 3.8%.</li><li>Store Count +4 Y/Y at 96.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393397-bassett-furniture-reports-q3-results\" target=\"_blank\">Bassett Furniture reports Q3 results</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393442\" data-linked=\"More on Bassett Furniture&#39;s Q3 results\" data-tweet=\"$BSET - More on Bassett Furniture&#39;s Q3 results https://seekingalpha.com/news/3393442-on-bassett-furnitures-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3393442-on-bassett-furnitures-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393440\" data-ts=\"1538057121\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALEAF\" target=\"_blank\">ALEAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393440-aleafia-health-up-2-on-mou-canntrust-for-15k-kg-of-cannabis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aleafia Health up 2% on MOU with CannTrust for 15K kg of cannabis</a></h4><ul><li>Aleafia Health (<a href='https://seekingalpha.com/symbol/ALEAF' title='Aleafia Health Inc.'>OTCQX:ALEAF</a> <font color='green'>+1.5%</font>) is up on double normal volume in reaction to its memorandum of understanding &#40;MOU&#41; with CannTrust Holdings (<a href='https://seekingalpha.com/symbol/CNTTF' title='Canntrust Holdings Inc.'>OTC:CNTTF</a> <font color='red'>-1.6%</font>) to <a href=\"https://seekingalpha.com/pr/17283513-aleafia-signs-cannabis-supply-mou-canntrust-15000-kg-2019\" target=\"_blank\">supply </a>up the 15,000 kg of cannabis.</li><li>The company says it will reach a fully funded growing capacity of 38,000 kg of cannabis flower in Q1 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393440\" data-linked=\"Aleafia Health up 2% on MOU with CannTrust for 15K kg of cannabis\" data-tweet=\"$ALEAF $ALEAF $CTST - Aleafia Health up 2% on MOU with CannTrust for 15K kg of cannabis https://seekingalpha.com/news/3393440-aleafia-health-up-2-on-mou-canntrust-for-15k-kg-of-cannabis?source=tweet\" data-url=\"https://seekingalpha.com/news/3393440-aleafia-health-up-2-on-mou-canntrust-for-15k-kg-of-cannabis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393432\" data-ts=\"1538056356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHN\" target=\"_blank\">ATHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393432-multiple-offers-for-athenahealth-cnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Multiple offers for athenahealth - CNBC</a></h4><ul><li>According to CNBC's David Faber, athenahealth (<a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a> <font color='green'>+1.9%</font>) has received multiple offers, supposedly only modestly above its current valuation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388341-cerner-unitedhealth-pass-athenahealth-shares-1-percent\" target=\"_blank\">Cerner and UnitedHealth pass on athenahealth; shares down 1%</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393432\" data-linked=\"Multiple offers for athenahealth - CNBC\" data-tweet=\"$ATHN - Multiple offers for athenahealth - CNBC https://seekingalpha.com/news/3393432-multiple-offers-for-athenahealth-cnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3393432-multiple-offers-for-athenahealth-cnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393433\" data-ts=\"1538056330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393433-match-groupplus-1_5-bumble-responds-to-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match Group +1.5% as Bumble responds to lawsuit</a></h4><ul><li>        Bumble responds to Match Group&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) patent infringement lawsuit.</li><li>               Bumble&rsquo;s formal response to the March lawsuit says the company believes &ldquo;all of the claims are baseless&rdquo; and Bumble is &ldquo;seeking to have several claims dismissed immediately, given their lack of merit.&rdquo;&nbsp;</li><li>               The company again accuses Match of interfering with its growth to acquire Bumble at a lower price.&nbsp;</li><li>               Key quote: &ldquo;Match did not invent the world of dating: men and especially women everywhere deserve the opportunity to connect with who they want, on their terms, and Bumble will continue to stand up for our users and our values as we take this battle to court.&rdquo;&nbsp;</li><li>               Read the full statement at <a href=\"https://techcrunch.com/2018/09/27/bumble-responds-to-match-groups-patent-infringement-lawsuit/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">TechCrunch</a>. &nbsp;&nbsp;</li><li>               Match Group shares are&nbsp;<font color='green'>up 1.5%</font>&nbsp;to $59.11.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392430-bumble-continues-match-countersuit-plans-ipo\" target=\"_blank\">Bumble continues Match countersuit, plans IPO</a> (Sept. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392521-match-group-responds-bumbles-suit-pursuit\" target=\"_blank\">Match Group responds to Bumble's suit pursuit</a> (Sept. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392616-tinder-tests-giving-women-control\" target=\"_blank\">Tinder tests giving women more control</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393433\" data-linked=\"Match Group +1.5% as Bumble responds to lawsuit\" data-tweet=\"$MTCH - Match Group +1.5% as Bumble responds to lawsuit https://seekingalpha.com/news/3393433-match-groupplus-1_5-bumble-responds-to-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3393433-match-groupplus-1_5-bumble-responds-to-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393426\" data-ts=\"1538055633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIPT\" target=\"_blank\">AIPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393426-precision-therapeutics-sells-first-streamway-in-europe-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Precision Therapeutics sells first Streamway in Europe; shares up 9%</a></h4><ul><li>Thinly traded nano cap Precision Therapeutics (<a href='https://seekingalpha.com/symbol/AIPT' title='Precision Therapeutics Inc.'>AIPT</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;on average volume on the <a href=\"https://seekingalpha.com/pr/17283238-precision-therapeutics-secures-first-streamway-system-sale-europe\" target=\"_blank\">news </a>that it has sold the first STREAMWAY System in Europe.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393426\" data-linked=\"Precision Therapeutics sells first Streamway in Europe; shares up 9%\" data-tweet=\"$AIPT $POAI - Precision Therapeutics sells first Streamway in Europe; shares up 9% https://seekingalpha.com/news/3393426-precision-therapeutics-sells-first-streamway-in-europe-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3393426-precision-therapeutics-sells-first-streamway-in-europe-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393421\" data-ts=\"1538055303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZEAL\" target=\"_blank\">ZEAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393421-zealand-pharma-launches-late-stage-study-of-dasiglucagon-in-diabetic-children\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zealand Pharma launches late-stage study of dasiglucagon in diabetic children</a></h4><ul><li>Zealand Pharma A/S (<a href='https://seekingalpha.com/symbol/ZEAL' title='Zealand Pharma'>ZEAL</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/17283340-zealand-pharma-initiated-phase-3-trial-dasiglucagon-treatment-severe-hypoglycemia-children\" target=\"_blank\">initiates </a>a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03667053?term=nct03667053&amp;rank=1\" target=\"_blank\">Phase 3 clinical trial</a> evaluating dasiglucagon for the treatment of severe insulin-induced hypoglycemia in children with type 1 diabetes.</li><li>The enrollment target for the randomized, placebo- and active-controlled study is 40 subjects. The primary endpoint will be the time to plasma glucose recovery (at least 20 mg/dL) from baseline without rescue IV glucose.</li><li>According to ClinicalTrials.gov, the estimated primary completion date is July 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393421\" data-linked=\"Zealand Pharma launches late-stage study of dasiglucagon in diabetic children\" data-tweet=\"$ZEAL - Zealand Pharma launches late-stage study of dasiglucagon in diabetic children https://seekingalpha.com/news/3393421-zealand-pharma-launches-late-stage-study-of-dasiglucagon-in-diabetic-children?source=tweet\" data-url=\"https://seekingalpha.com/news/3393421-zealand-pharma-launches-late-stage-study-of-dasiglucagon-in-diabetic-children\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393418\" data-ts=\"1538054900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393418-applied-optoelectronicsminus-8_9-after-loop-moves-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Optoelectronics -8.9% after Loop moves to Sell</a></h4><ul><li>        Loop Capital downgrades Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) from Hold to Sell and cuts the price target from $45 to $20.</li><li>               Analyst James Kisner cites reduced estimates after industry checks indicated product quality issues for AAOI&rsquo;s 100G CWDM4 transceivers and difficult pricing trends.&nbsp;</li><li>               Source: StreetAccount. &nbsp;&nbsp;</li><li>               Applied Optoelectronics shares are&nbsp;<font color='red'>down 8.9%</font>&nbsp;premarket to $28.55.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393418\" data-linked=\"Applied Optoelectronics -8.9% after Loop moves to Sell\" data-tweet=\"$AAOI - Applied Optoelectronics -8.9% after Loop moves to Sell https://seekingalpha.com/news/3393418-applied-optoelectronicsminus-8_9-after-loop-moves-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3393418-applied-optoelectronicsminus-8_9-after-loop-moves-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393412\" data-ts=\"1538054604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWPH\" target=\"_blank\">GWPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393412-gw-pharma-up-4-premarket-on-schedule-5-listing-for-epidiolex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GW Pharma up 4% premarket on Schedule 5 listing for Epidiolex</a></h4><ul><li>GW Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on modest volume in apparent reaction to the <a href=\"https://stocknews.com/news/gwph-headlines-that-the-dea-has-given-epidiolex-a-schedule-v/\" target=\"_blank\">news</a> that the U.S. Drug Enforcement Agency &#40;DEA&#41; has categorized Epidiolex (cannabidiol) as a Schedule 5 drug, a classification for medications with lower abuse potential that Schedule 4 (e.g., Xanax, Darvon, Ambien).</li><li>Schedule 5, the DEA's lowest category for controlled substances, includes cough suppressants containing modest amounts of codeine (e.g., Robitussin AG), Lyrica and Motofen.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3391516-u-s-dea-classify-gw-pharmas-epidiolex-shares-8-percent\" target=\"_blank\">U.S. DEA to down-classify GW Pharma's Epidiolex; shares up 8%</a> (Sept. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393412\" data-linked=\"GW Pharma up 4% premarket on Schedule 5 listing for Epidiolex\" data-tweet=\"$GWPH - GW Pharma up 4% premarket on Schedule 5 listing for Epidiolex https://seekingalpha.com/news/3393412-gw-pharma-up-4-premarket-on-schedule-5-listing-for-epidiolex?source=tweet\" data-url=\"https://seekingalpha.com/news/3393412-gw-pharma-up-4-premarket-on-schedule-5-listing-for-epidiolex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393409\" data-ts=\"1538054426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRUP\" target=\"_blank\">TRUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393409-buy-dip-in-trupanion-raymond-james\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buy the dip in Trupanion - Raymond James</a></h4><ul><li>Trupanion (NYSE:<a href='https://seekingalpha.com/symbol/TRUP' title='Trupanion'>TRUP</a>)<font color='red'> tumbled more than 10%&nbsp;</font>on what turned out to be a mistaken report of a probe by the NY Department of Financial Services.</li><li>That's manna for long-term investors able to weather \"potential noise,\" says analyst John Ransom.</li><li>\"We have yet to see evidence that would spark a shift in our general thinking,\" he says. Ransom continues to rate the stock Outperform.</li><li>Shares are<font color='green'> higher by 1.7%&nbsp;</font>in premarket action.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393175-report-trupanion-probe-walked-back-shares-remain-5-percent\" target=\"_blank\">Report on Trupanion probe is walked back; shares remain down 5%</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393409\" data-linked=\"Buy the dip in Trupanion - Raymond James\" data-tweet=\"$TRUP - Buy the dip in Trupanion - Raymond James https://seekingalpha.com/news/3393409-buy-dip-in-trupanion-raymond-james?source=tweet\" data-url=\"https://seekingalpha.com/news/3393409-buy-dip-in-trupanion-raymond-james\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393403\" data-ts=\"1538054065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERU\" target=\"_blank\">VERU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393403-veru-prices-stock-offering-1_40-shares-down-18-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veru prices stock offering at $1.40; shares down 18% premarket</a></h4><ul><li>Veru (NASDAQ:<a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a>) <a href=\"https://seekingalpha.com/pr/17283480-veru-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of ~7.1M shares of common stock at $1.40 per share. Underwriters over-allotment is an additional ~1.1M shares. Closing date is October 1.</li><li>Yesterday's close was $1.70. Shares are down&nbsp;<font color='red'>18%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393403\" data-linked=\"Veru prices stock offering at $1.40; shares down 18% premarket\" data-tweet=\"$VERU - Veru prices stock offering at $1.40; shares down 18% premarket https://seekingalpha.com/news/3393403-veru-prices-stock-offering-1_40-shares-down-18-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3393403-veru-prices-stock-offering-1_40-shares-down-18-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393402\" data-ts=\"1538053919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHV\" target=\"_blank\">ACHV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393402-premarket-gainers-of-9-05-09-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (09/27/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='green'>+35%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393351-achieve-life-sciences-38-percent-premarket-performance-new-cytisine-formulation\" target=\"_blank\">performance</a> of new cytisine formulation.</li><li><a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+14%&nbsp;</font>after <a href=\"https://seekingalpha.com/news/3393342-cameco-plus-16-percent-winning-canada-tax-dispute\" target=\"_blank\">winning</a> Canada tax dispute.</li><li><a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+9%</font>.</li><li>RXII <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/GNPX' title='Genprex, Inc'>GNPX</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17283056-genprex-taps-aldevron-supply-tusc2-plasmid-dna-oncoprex-clinical-development-program\" target=\"_blank\">agreement</a> with Aldevron to supply TUSC2 plasmid DNA for use in Genprex&rsquo;s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.</li><li><a href='https://seekingalpha.com/symbol/AIPT' title='Precision Therapeutics Inc.'>AIPT</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17283238-precision-therapeutics-secures-first-streamway-system-sale-europe\" target=\"_blank\">securing</a> its first European sale of the&nbsp;STREAMWAY System.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393402\" data-linked=\"Premarket Gainers as of 9:05 am (09/27/2018)\" data-tweet=\"$ACHV $ACHV $CCJ - Premarket Gainers as of 9:05 am (09/27/2018) https://seekingalpha.com/news/3393402-premarket-gainers-of-9-05-09-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393402-premarket-gainers-of-9-05-09-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393401\" data-ts=\"1538053885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GERN\" target=\"_blank\">GERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393401-premarket-losers-of-9-05-9-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (9/27/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a>&nbsp;<font color='red'>-69%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393313-geron-announces-discontinuation-imetelstat-collaboration-janssen-shares-68-percent-premarket\" target=\"_blank\">announcing</a> discontinuation of Imetelstat collaboration by Janssen.</li><li><a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393226-bed-bath-and-beyond-misses-0_14-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393248-comtech-telecommunications-beats-0_14-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical'>OASM</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/KRP' title='Kimbell Royalty Partners LP'>KRP</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393272-kimbell-royalty-partners-launches-3m-unit-public-offering\" target=\"_blank\">announcing</a> public offering of Common Units.</li><li><a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393345-conagra-brands-misses-0_02-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393401\" data-linked=\"Premarket Losers as of 9:05 am (9/27/2018)\" data-tweet=\"$GERN $GERN $BBBY - Premarket Losers as of 9:05 am (9/27/2018) https://seekingalpha.com/news/3393401-premarket-losers-of-9-05-9-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3393401-premarket-losers-of-9-05-9-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393394\" data-ts=\"1538053331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393394-amyris-inks-development-deal-yifan-pharmaceutical-shares-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris inks development deal with Yifan Pharmaceutical; shares up 8% premarket</a></h4><ul><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) closes a multiyear <a href=\"https://seekingalpha.com/pr/17283269-amyris-enters-extensive-collaboration-agreement-leading-chinese-pharmaceutical-company-yifan\" target=\"_blank\">agreement </a>with a subsidiary of Chinese outfit Yifan Pharmaceutical Company aimed at developing active pharmaceutical ingredients (APIs), including nutritional products, biologics, small molecule drugs and traditional Chinese medicine, in China and the rest of the world.</li><li>First up is developing a key unnamed molecule in nutrition that Amyris CEO John Melo says could generate $100M in revenue.</li><li>Financial terms are not disclosed.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393394\" data-linked=\"Amyris inks development deal with Yifan Pharmaceutical; shares up 8% premarket\" data-tweet=\"$AMRS - Amyris inks development deal with Yifan Pharmaceutical; shares up 8% premarket https://seekingalpha.com/news/3393394-amyris-inks-development-deal-yifan-pharmaceutical-shares-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3393394-amyris-inks-development-deal-yifan-pharmaceutical-shares-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393390\" data-ts=\"1538052773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBMG\" target=\"_blank\">CBMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393390-cellular-biomedicine-inks-deal-novartis-for-car-t-cell-therapy-for-patients-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellular Biomedicine inks deal with Novartis for CAR-T cell therapy for patients in China</a></h4><ul><li>Cellular Biomedicine Group&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/CBMG' title='Cellular Biomedicine Group, Inc.'>CBMG</a>) has <a href=\"https://seekingalpha.com/pr/17283007-cellular-biomedicine-group-enters-strategic-licensing-collaboration-agreement-global-leader\" target=\"_blank\">entered</a> into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.</li><li>Upon the closing of the agreement, CBMG will receive $40M in an equity purchase from Novartis at $27.43/share for ~9% equity. Novartis will receive certain royalty-free intellectual property worldwide rights to certain CBMG CAR-T related technology. CBMG will receive a single-digit percentage collaboration payment based on net product sales and a mark-up from Novartis on the manufacturing cost.</li><li>CBMG will take the lead in the manufacturing process, and Novartis will lead distribution, regulatory and commercialization efforts in China.</li><li>CBMG shares are up&nbsp;<font color='green'>11%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393390\" data-linked=\"Cellular Biomedicine inks deal with Novartis for CAR-T cell therapy for patients in China\" data-tweet=\"$CBMG - Cellular Biomedicine inks deal with Novartis for CAR-T cell therapy for patients in China https://seekingalpha.com/news/3393390-cellular-biomedicine-inks-deal-novartis-for-car-t-cell-therapy-for-patients-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3393390-cellular-biomedicine-inks-deal-novartis-for-car-t-cell-therapy-for-patients-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393381\" data-ts=\"1538051658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STZ\" target=\"_blank\">STZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393381-green-light-for-constellation-canopy-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Green light for Constellation-Canopy deal</a></h4><ul> <li>Constellation Brands' (NYSE:<a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a>) $4B investment in Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) through an affiliate was approved by the Canopy board yesterday.</li>                 <li>\"With shareholders aligned on our vision of the future we'll get to work deploying capital and creating even more value for the hundreds of thousands of people who trust us with their hard-earned money,\" says Canopy Co-CEO&nbsp;Bruce Linton.</li><li>Constellation is landing board representation at Canopy through the addition of&nbsp; CBG Holdings nominees.</li>  <li>CGC  <font color='green'>+1.17%</font> premarket to  $52.61.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17282670-canopy-growth-shareholders-approve-5b-cad-4b-usd-investment-constellation-brands\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3393381\" data-linked=\"Green light for Constellation-Canopy deal\" data-tweet=\"$STZ $STZ $CGC - Green light for Constellation-Canopy deal https://seekingalpha.com/news/3393381-green-light-for-constellation-canopy-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3393381-green-light-for-constellation-canopy-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393377\" data-ts=\"1538051525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOVA\" target=\"_blank\">DOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393377-dova-pharma-to-co-promote-doptelet-in-u-s-salix-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dova Pharma to co-promote Doptelet in U.S. with Salix Pharma</a></h4><ul><li>Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a>) inks an <a href=\"https://seekingalpha.com/pr/17283038-dova-pharmaceuticals-salix-enter-exclusive-co-promotion-agreement-doptelet-avatrombopag\" target=\"_blank\">agreement </a>with Bausch Health Companies' (NYSE:<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a>) Salix Pharmaceuticals to co-promote DOPTELET (avatrombopag) in the U.S.</li><li>Salix plans to deploy ~100 sales reps to promote DOPTELET to healthcare professionals in gastroenterology beginning next month while Dova will continue its promotional activities with hepatologists, interventional radiologists and certain other specialties. Dova will pay Salix a quarterly fee based on net sales of DOPTELET prescribed by gastroenterologists.</li><li>The FDA approved DOPTELET about four months ago for thrombocytopenia in adults with chronic liver disease who are about to undergo a procedure.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3358283-fda-oks-dova-pharmas-avatrombopag\" target=\"_blank\">FDA OK's Dova Pharma's avatrombopag</a> (May 21)</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393377\" data-linked=\"Dova Pharma to co-promote Doptelet in U.S. with Salix Pharma\" data-tweet=\"$DOVA $DOVA $BHC - Dova Pharma to co-promote Doptelet in U.S. with Salix Pharma https://seekingalpha.com/news/3393377-dova-pharma-to-co-promote-doptelet-in-u-s-salix-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3393377-dova-pharma-to-co-promote-doptelet-in-u-s-salix-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393370\" data-ts=\"1538051139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393370-conagra-brands-trades-weak-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra Brands trades weak after earnings</a></h4><ul> <li>ConAgra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>) trades lower after organic sales only increased 1.2% in <a href=\"https://seekingalpha.com/pr/17282997-conagra-brands-reports-solid-first-quarter-results\" target=\"_blank\">FQ1</a> off of flat volume.</li> <li>Organic sales rose 6.3% for the international business, but were only up 0.2% for the grocery/snacks and foodservices segments.</li> <li>The company's gross margin fell 60 bps Y/Y to 28.6% of sales vs. 28.5% consensus.</li> <li>ConAgra management says the acquisition of Pinnacle Foods (NYSE:<a href='https://seekingalpha.com/symbol/PF' title='Pinnacle Foods'>PF</a>) is expected to close by the end of October.</li> <li>Looking ahead, ConAgra sees sales growth in the range of 0.5% to 1.5% for FY19 and organic sales growth of 1.0% to 2.0%. Adjusted operating margin is seen falling in the range of 15.0% to 15.3%.</li> <li>CAG <font color='red'>-6.87%</font> premarket to $33.60. The 52-week low for shares is $32.90.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393345-conagra-brands-misses-0_02-misses-revenue\" target=\"_blank\">ConAgra Brands misses by $0.02, misses on revenue</a> (Sept. 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393370\" data-linked=\"ConAgra Brands trades weak after earnings\" data-tweet=\"$CAG $CAG $PF - ConAgra Brands trades weak after earnings https://seekingalpha.com/news/3393370-conagra-brands-trades-weak-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3393370-conagra-brands-trades-weak-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393368\" data-ts=\"1538050952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393368-northland-capital-downgrades-amd-on-irrational-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northland Capital downgrades AMD on &quot;irrational expectations&quot;</a></h4><ul><li>        Northland Capital Markets <a href=\"https://www.streetinsider.com/Analyst+Comments/Northland+Capital+Markets+Downgrades+AMD+%28AMD%29+to+Market+Perform/14648545.html\" target=\"_blank\">downgrades</a> AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) from Outperform to Market Perform and lowers the target from $30 to $26, a 19% downside to yesterday&rsquo;s close.</li><li>               Analyst Gus Richard says the slowing of Moore&rsquo;s law, AMD&rsquo;s strong design team, and its strong IP position led the firm to think AMD would challenge Intel.&nbsp;</li><li>               Richard: &ldquo;Our thesis hasn&rsquo;t changed, valuation and sentiment has. While we expect shares to continue to appreciate between now and 12/31, we think the share price reflects irrational expectations.&rdquo;&nbsp;</li><li>               AMD shares are&nbsp;<font color='red'>down 0.9%</font>&nbsp;premarket to $31.90. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392156-jefferies-amds-market-share-triple-intel-issues\" target=\"_blank\">Jefferies: AMD's market share could triple on Intel issues</a> (Sept. 21)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392372-rbc-presents-amd-bull-case-reports-sell-side-firm-questioning-share-gain\" target=\"_blank\">RBC presents AMD bull case; reports of sell-side firm questioning share gain</a> (Sept. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392761-raymond-james-downgrades-intel-10nm-delay\" target=\"_blank\">Raymond James downgrades Intel on 10nm delay</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393368\" data-linked=\"Northland Capital downgrades AMD on &quot;irrational expectations&quot;\" data-tweet=\"$AMD - Northland Capital downgrades AMD on &quot;irrational expectations&quot; https://seekingalpha.com/news/3393368-northland-capital-downgrades-amd-on-irrational-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3393368-northland-capital-downgrades-amd-on-irrational-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>145&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393366\" data-ts=\"1538050730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTGX\" target=\"_blank\">PTGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393366-fda-grants-fast-track-designation-to-protagonist-therapeutics-ptgminus-300\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants Fast Track designation to Protagonist Therapeutics&#39; PTG-300</a></h4><ul><li>Protagonist Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a>) <a href=\"https://seekingalpha.com/pr/17282937-protagonist-therapeutics-announces-fast-track-designation-granted-u-s-fda-hepcidin-mimetic\" target=\"_blank\">announces</a> that the FDA has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-thalassemia.</li><li>PTG-300 is an injectable hepcidin mimetic that has been granted Orphan Drug Designation by the FDA for beta-thalassemia, a rare disease characterized by iron overload.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3393366\" data-linked=\"FDA grants Fast Track designation to Protagonist Therapeutics&#39; PTG-300\" data-tweet=\"$PTGX - FDA grants Fast Track designation to Protagonist Therapeutics&#39; PTG-300 https://seekingalpha.com/news/3393366-fda-grants-fast-track-designation-to-protagonist-therapeutics-ptgminus-300?source=tweet\" data-url=\"https://seekingalpha.com/news/3393366-fda-grants-fast-track-designation-to-protagonist-therapeutics-ptgminus-300\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393357\" data-ts=\"1538049878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYBR\" target=\"_blank\">CYBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393357-cyberarkplus-4-on-morgan-stanley-upgrade-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CyberArk +4% on Morgan Stanley upgrade, target boost</a></h4><ul><li>        Morgan Stanley upgrades CyberArk Software (NASDAQ:<a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a>) from Equal Weight to Overweight and increases the target from $71 to $92, a 25% upside to yesterday&rsquo;s close. &nbsp;</li><li>        Source: <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Upgrades+CyberArk+Software+%28CYBR%29+to+Overweight/14648525.html\" target=\"_blank\">StreetInsider</a>.</li><li>               CyberArk has benefitted from several global cybersecurity headlines driving the sector up and from its acquisition focus. In the past year, CyberArk has acquired DevOps security company Conjur and cloud security firm Vaultive. &nbsp;&nbsp;</li><li>               CyberArk shares are&nbsp;<font color='green'>up 4.2%</font>&nbsp;premarket to $76.55. Shares are&nbsp;<font color='green'>up 18.6%</font>&nbsp;in the quarter and&nbsp;<font color='green'>77.6%</font>&nbsp;YTD.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393357\" data-linked=\"CyberArk +4% on Morgan Stanley upgrade, target boost\" data-tweet=\"$CYBR - CyberArk +4% on Morgan Stanley upgrade, target boost https://seekingalpha.com/news/3393357-cyberarkplus-4-on-morgan-stanley-upgrade-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3393357-cyberarkplus-4-on-morgan-stanley-upgrade-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393351\" data-ts=\"1538049350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHV\" target=\"_blank\">ACHV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393351-achieve-life-sciences-up-38-premarket-on-performance-of-new-cytisine-formulation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achieve Life Sciences up 38% premarket on performance of new cytisine formulation</a></h4><ul><li>Nano cap Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) is up&nbsp;<font color='green'>38%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17282850-achieve-announces-results-clinical-study-demonstrating-similar-bioavailability-new-cytisine\" target=\"_blank\">announcement </a>that a new formulation of smoking cessation candidate cytisine demonstrated bioequivalence in healthy volunteer smokers with or without food. The results were similar to the previous formation that showed bioequivalence in healthy non-smoking volunteers.</li><li>Chairman &amp; CEO Rick Stewart says, \"We believe this new cytisine formulation will allow for an extended shelf-life and will be used in the upcoming Phase 2b clinical trial as well as the Phase 3 clinical program. We are pleased with the similar results regarding this new formulation in smokers and that the higher dose of 3 mg cytisine continues to demonstrate a good safety profile with or without food.\"</li><li>Cytisine is a plant-based alkaloid with a strong affinity to the nicotinic acetylcholine receptor.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3369186-achieve-life-sciences-19-percent-premarket-cytisine-development-plan\" target=\"_blank\">Achieve Life Sciences up 19% premarket on cytisine development plan</a> (July 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393351\" data-linked=\"Achieve Life Sciences up 38% premarket on performance of new cytisine formulation\" data-tweet=\"$ACHV - Achieve Life Sciences up 38% premarket on performance of new cytisine formulation https://seekingalpha.com/news/3393351-achieve-life-sciences-up-38-premarket-on-performance-of-new-cytisine-formulation?source=tweet\" data-url=\"https://seekingalpha.com/news/3393351-achieve-life-sciences-up-38-premarket-on-performance-of-new-cytisine-formulation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393349\" data-ts=\"1538048767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393349-aptose-biosciences-and-crystalgenomics-announce-issuance-of-european-patent-for-cgminus-806\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptose Biosciences and CrystalGenomics announce issuance of European patent for CG-806</a></h4><ul> <li>Aptose Biosciences&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) <a href=\"https://seekingalpha.com/pr/17282978-aptose-biosciences-crystalgenomics-announce-issuance-european-patent-cgminus-806\" target=\"_blank\">announces</a> that the European Patent Office has issued European Patent No. EP2940014B1 for CG-806, a highly potent oral small molecule being developed for acute myeloid leukemia &#40;AML&#41;, B cell and other hematologic malignancies.</li><li>The&nbsp;granted&nbsp;patent claims&nbsp;various compounds, compositions and&nbsp;uses&nbsp;for the treatment of various diseases, such as cancer.&nbsp;This European patent will be nationalized in, and cover, approx. 40 European countries. The patent is expected to provide protection until the end of 2033.</li><li>APTO shares are up&nbsp;<font color='green'>5%</font>&nbsp;premarket.</li>       </ul><div class=\"tiny-share-widget\" data-id=\"3393349\" data-linked=\"Aptose Biosciences and CrystalGenomics announce issuance of European patent for CG-806\" data-tweet=\"$APTO - Aptose Biosciences and CrystalGenomics announce issuance of European patent for CG-806 https://seekingalpha.com/news/3393349-aptose-biosciences-and-crystalgenomics-announce-issuance-of-european-patent-for-cgminus-806?source=tweet\" data-url=\"https://seekingalpha.com/news/3393349-aptose-biosciences-and-crystalgenomics-announce-issuance-of-european-patent-for-cgminus-806\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393348\" data-ts=\"1538048714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLNX\" target=\"_blank\">XLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393348-needham-starts-xilinx-buy-on-fpga-growth-phase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham starts Xilinx at Buy on FPGA growth phase</a></h4><ul><li>        Needham <a href=\"https://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Starts+Xilinx+%28XLNX%29+at+Buy/14648715.html\" target=\"_blank\">initiates</a> Xilinx (NASDAQ:<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a>) at Buy with a $100 price target, a 28% upside to yesterday&rsquo;s close.</li><li>               Analyst Quinn Bolton believes the &ldquo;FPGA segment is entering a new growth phase driven by the adoption of accelerated computing&rdquo; and cites the firm&rsquo;s proprietary survey as showing Xilinx poised for data center share gains. &nbsp;&nbsp;</li><li>                  Xilinx shares are<font color='green'>&nbsp;up 0.5%</font>&nbsp;premarket to $78.71.&nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3393348\" data-linked=\"Needham starts Xilinx at Buy on FPGA growth phase\" data-tweet=\"$XLNX - Needham starts Xilinx at Buy on FPGA growth phase https://seekingalpha.com/news/3393348-needham-starts-xilinx-buy-on-fpga-growth-phase?source=tweet\" data-url=\"https://seekingalpha.com/news/3393348-needham-starts-xilinx-buy-on-fpga-growth-phase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393347\" data-ts=\"1538048506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393347-alnylams-givosiran-shows-positive-effect-in-late-stage-ahp-study-u-s-marketing-application\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam&#39;s givosiran shows positive effect in late-stage AHP study; U.S. marketing application planned; shares ahead 2% premarket</a></h4><ul><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17282930-alnylam-announces-positive-topline-results-interim-analysis-envision-phase-3-study-givosiran\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03338816?titles=envision&amp;lead=alnylam&amp;phase=2&amp;rank=1\" target=\"_blank\">ENVISION</a>, evaluating givosiran in patients with <a href=\"https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=95157\" target=\"_blank\">acute hepatic porphyria</a> &#40;AHP&#41;, an inherited disorder affecting the production of heme, the iron-containing part of hemoglobin that binds with oxygen. Patients suffering from AHP experience intense abdominal pain and fatigue and neurological and psychological symptoms.</li><li>The primary endpoint was the annualized rate of porphyria attacks in patients with acute intermittent porphyria &#40;AIP&#41; at month 6 compared to placebo. This outcome will be reported in early 2019.</li><li>The company says&nbsp; the interim analysis was based on lowering urinary aminolevulinic acid &#40;ALA&#41;, a surrogate biomarker that it says is reasonably likely to predict clinical benefit.&nbsp;The data showed treatment with givosiran resulted in a statistically significant reduction in urinary ALA compared to control (p&lt;0.001).</li><li>Alnylam intends to discuss the data with the FDA as well as a regulatory path for the indication. If all goes well, a marketing application will be filed around year-end.</li><li>Givosiran (formerly ALN-AS1) is an RNAi therapeutic that targets an enzyme called aminolevulinic acid synthase 1 (ALAS1).</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393347\" data-linked=\"Alnylam&#39;s givosiran shows positive effect in late-stage AHP study; U.S. marketing application planned; shares ahead 2% premarket\" data-tweet=\"$ALNY - Alnylam&#39;s givosiran shows positive effect in late-stage AHP study; U.S. marketing application planned; shares ahead 2% premarket https://seekingalpha.com/news/3393347-alnylams-givosiran-shows-positive-effect-in-late-stage-ahp-study-u-s-marketing-application?source=tweet\" data-url=\"https://seekingalpha.com/news/3393347-alnylams-givosiran-shows-positive-effect-in-late-stage-ahp-study-u-s-marketing-application\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393342\" data-ts=\"1538048140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCJ\" target=\"_blank\">CCJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393342-camecoplus-16-after-winning-canada-tax-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cameco +16% after winning Canada tax dispute</a></h4><ul>     <li>Cameco (NYSE:<a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a>)&nbsp;<font color='green'>+16.2%</font> pre-market after the Tax Court of Canada <a href=\"https://seekingalpha.com/pr/17282773-tax-court-canada-rules-favour-cameco\" target=\"_blank\">ruled in its favor</a> in the dispute of the reassessments issued by Canada Revenue Agency for the 2003, 2005 and 2006 tax years.</li>     <li>The Tax Court rules CCJ's marketing and trading structure involving foreign subsidiaries and the related transfer pricing methodology used for certain inter-company uranium sale and purchase agreements are in full compliance with Canadian laws for the tax years in question.</li><li>CCJ says it will apply to the court to recover the substantial costs incurred over the course of the case.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393342\" data-linked=\"Cameco +16% after winning Canada tax dispute\" data-tweet=\"$CCJ - Cameco +16% after winning Canada tax dispute https://seekingalpha.com/news/3393342-camecoplus-16-after-winning-canada-tax-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3393342-camecoplus-16-after-winning-canada-tax-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393340\" data-ts=\"1538047711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393340-jpmorgan-starts-apple-overweight-on-services-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan starts Apple at Overweight on services potential</a></h4><ul><li>        JPMorgan<a href=\"https://www.cnbc.com/2018/09/27/jp-morgan-says-buy-apple-shares-due-to-its-services-transformation.html\" target=\"_blank\"> initiates</a> Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) at Overweight due to the tech giant &ldquo;transforming from a hardware company to a services company faster than investors had expected, which is driving financial and valuation upside.&rdquo;</li><li>               Analyst Samik Chatterjee notes that Apple&rsquo;s services sales rose to 13% of its FY17 revenue versus the 8% in FY12. He forecasts growth to 20% of sales by FY21.&nbsp;</li><li>               Chatterjee is the new Apple analyst at the firm, which last covered the company in October last year.&nbsp;</li><li>               Price target: $272, a 23% upside to yesterday&rsquo;s close.&nbsp;&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $223.10.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3393340\" data-linked=\"JPMorgan starts Apple at Overweight on services potential\" data-tweet=\"$AAPL - JPMorgan starts Apple at Overweight on services potential https://seekingalpha.com/news/3393340-jpmorgan-starts-apple-overweight-on-services-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3393340-jpmorgan-starts-apple-overweight-on-services-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393339\" data-ts=\"1538047519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393339-rite-aidminus-1-after-mixed-earnings-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid -1% after mixed earnings report</a></h4><ul> <li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) is&nbsp;<font color='red'>down 1%</font>&nbsp;in premarket trading after posting a mixed <a href=\"https://seekingalpha.com/pr/17282926-rite-aid-reports-fiscal-2019-second-quarter-results\" target=\"_blank\">FQ2</a> report and affirming prior guidance for FY19 revenue and same-store sales growth.</li>  <li>Retail pharmacy same-store sales were up 1% in Q2, consisting of a 1.6% increase in pharmacy sales and 0.1% decline in front-end sales.</li> <li>Rite Aid's net loss widened to $352M from $188M a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393326-rite-aid-eps-line-beats-revenue\" target=\"_blank\">Rite Aid EPS in-line, beats on revenue</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393336-rite-aid-announces-board-changes\" target=\"_blank\">Rite Aid announces board changes</a> (Sept. 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3393339\" data-linked=\"Rite Aid -1% after mixed earnings report\" data-tweet=\"$RAD - Rite Aid -1% after mixed earnings report https://seekingalpha.com/news/3393339-rite-aidminus-1-after-mixed-earnings-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3393339-rite-aidminus-1-after-mixed-earnings-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>268&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393336\" data-ts=\"1538047111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393336-rite-aid-announces-board-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid announces board changes</a></h4><ul> <li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) announces the nomination of three       new independent directors and says it will separate the positions of chairman and CEO.</li>     <li>The three new independent director nominees are&nbsp;Robert Knowling (Chairman Eagles Landing Partners), Louis Miramontes (KPMG exec)&nbsp;and Arun Nayar (former Tyco CFO)..</li><li>Bruce Bodaken will hold the       position of chairman, effective at the annual meeting.</li><li>The company's annual meeting is scheduled for October 30.</li><li>\"These changes will significantly strengthen and enhance the Board&rsquo;s       governance oversight and reflect our commitment to aligning Rite Aid&rsquo;s       interests with those of stockholders,\" says Bodaken.</li>          <li>RAD  <font color='green'>+2.34%</font> premarket to  $1.31.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17282907-rite-aid-announces-board-governance-changes\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3393326-rite-aid-eps-line-beats-revenue\" target=\"_blank\">Rite Aid EPS in-line, beats on revenue</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3393336\" data-linked=\"Rite Aid announces board changes\" data-tweet=\"$RAD - Rite Aid announces board changes https://seekingalpha.com/news/3393336-rite-aid-announces-board-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/3393336-rite-aid-announces-board-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}